Halozyme(US:HALO)2026-03-11 15:47Halozyme Therapeutics Conference Call Summary Company Overview - Company: Halozyme Therapeutics (NasdaqGS: HALO) - Conference Date: March 11, 2026 - Expected Revenue: $1.7-$1.8 billion for 2026, representing a 22%-30% year-over-year growth [1][2] Key Products Driving Growth - Main Revenue Drivers: - DARZALEX FASPRO: Leading product with strong growth due to subcutaneous delivery [2] - VYVGART HYTRULO: Significant contributor with 100% year-over-year growth, driven by the adoption of the pre-filled syringe [8][10] - Roche's Perjeta: Transitioning to subcutaneous delivery, achieving a 52% conversion rate in the U.S. with a target of 60% by 2028 [6][5] Additional Product Opportunities - Emerging Products: Four recently launched products (Opdivo, OCREVUS, RYBREVANT, Tecentriq) expected to contribute significantly in 2026 [3][15] - OCREVUS: Roche's drug for multiple sclerosis, with a potential market expansion due to subcutaneous delivery, aiming for a $2 billion increase in sales [17][18] - RYBREVANT: Johnson & Johnson's lung cancer drug, transitioning from a 5-hour IV infusion to a 5-minute subcutaneous administration, aiming for a $5 billion brand [22][23] Strategic Partnerships and Deals - New Partnerships: Three new deals signed at the end of 2025, with expectations for at least three new deals in 2026 [27] - Current Partner Expansion: Existing partners are increasing their nominations for new drugs, indicating strong momentum [26] Development Pipeline - Current Development: Seven products in development with ENHANZE, including collaborations with argenx and Takeda [30] - Future Projections: Expectation of 40 approved or in-development drugs by 2028, with six new ENHANZE phase 1 starts this year [31] Litigation Update - Merck Litigation: Ongoing litigation regarding MDASE patents, with Halozyme confident in its position. Positive outcomes in Germany have halted Merck's launch of SubQ Keytruda [34][36] Acquisitions and Technology Expansion - Recent Acquisitions: - Elektrofi: Acquired for its Hypercon technology, enhancing subcutaneous delivery capabilities [37] - Surf Bio: Acquired for a different approach to hyperconcentration, expanding Halozyme's market opportunities [39] - Market Acceptance: Increased acceptance of subcutaneous delivery among partners, with expectations for 5-7 launches by the mid-2030s [44] Financial Guidance and Future Outlook - Long-term Guidance: Confidence in achieving $1 billion in royalties from Hypercon by the mid-2030s, based on partner plans and market acceptance [43][44] - Growth Ambitions: Continued focus on M&A to add assets with recurring royalty-like revenue, aiming for sustained growth [49][50]